Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 10190Neoplasms 7819Carcinoma, Non-Small-Cell Lung 5763Prostatic Neoplasms 5032Colorectal Neoplasms 4608Lung Neoplasms 3727Leukemia, Myeloid, Acute 3104Neoplasm Metastasis 3086Multiple Myeloma 3083Pancreatic Neoplasms 2846Melanoma 2654Ovarian Neoplasms 2578Lymphoma 2571Carcinoma, Hepatocellular 2483Stomach Neoplasms 2331Recurrence 2229Head and Neck Neoplasms 2106Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1906Glioblastoma 1799Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1695Lymphoma, Follicular 1655Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Large B-Cell, Diffuse 1598Carcinoma, Renal Cell 1579

Interventions

Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hematopoietic System--Cancer × Clear all
NCT03654703 2018-08-31

Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML

Capital Research Institute of Pediatrics

Phase 2 Unknown
100 enrolled

Hematopoietic System--Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡